Growth
Private Company Edition: ARCH raised more than $3bn for its eighth fund, Frazier added $630m to its public fund that also can back crossover rounds, DCVC’s third biotech fund totaled $400m and Asabys raised €180m ($200m) for its second fund. Also, Aktis closed a $175m series B round.
BridgeBio spun out oncology assets in May to focus on rare diseases and now it has sliced off a few rare disease candidates for GondolaBio. Also, Avidity and Kymera closed follow-on offerings that grossed $345.1m and $225m, respectively, and Vandria extended its series A round to $30.7m.
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.
As it considers what route to take to independence, Sanofi's Consumer Healthcare business – recently rebranded as Opella – has been changing its approach to marketing, according to chief growth officer Alberto Hernandez. In this exclusive interview, Hernandez explains how “Crazy Elevating Creativity” is delivering real results for Sanofi's top OTC brands.
Incyte reported positive topline Phase III results for Monjuvi in relapsed or refractory follicular lymphoma and plans to file for US FDA approval by the end of 2024.
Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
George Badescu, chief business officer at Heidelberg Pharma, discusses antibody-drug conjugate development, partnership styles and the appetite for risk-taking in the biopharma industry.
Private Company Edition: Symbiotic Capital emerged with a $600m-plus fund to provide credit for private and public companies, while venBio raised a $528m fund. Also, Outpace Bio raised $144m, Jade Biosciences launched with $80m and MBX Biosciences raised $63.5m.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Public Company Edition: OS Therapies launched this year’s smallest initial public offering, to fund its lead program in osteosarcoma. Also, Australian firm Telix, after opting out of a US IPO, grossed A$650m ($425.5m) from investors at home. Day One raised $175m in a private placement.
Second quarter revenues are up but RSV jab woes drag on the company’s stock.
Merck & Co.’s $16.11bn in sales exceeded expectations and prompted a slight increase in 2024 guidance, but HPV vaccine Gardasil came in slightly below consensus due to lower sales in China.
Sales of the Swiss group’s bispecific in retinal vein occlusion are forecast to increase out to 2030 as sales of Eylea and Lucentis fall.
Bristol’s CEO offered assurances about Medicare negotiations under the IRA as the company delivered better-than-expected second quarter results across new and legacy products.
Beyfortus was a minimal contributor in Sanofi’s second quarter, which beat consensus and prompted an earnings guidance boost, but the RSV antibody’s sales should surge in Q3 and Q4.
Autobahn raised $100m in series C venture capital to take its oral, brain-penetrant thyromimetic ABX-002 into Phase II studies in major depressive disorder and bipolar disorder depression.
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.
Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.
ADVERTISEMENT